PVI
SAGE

Pura Vida Investments’s Sage Therapeutics SAGE Stock Holding History

Pura Vida Investments’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$1.4M – 116
2019
Q3 		$1.4M Buy
+10,000
New +$1.67M 0.24% 73

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pura Vida Investments's SAGE Position: Q2 2019 in Review

Pura Vida Investments sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 10,000 shares — an estimated $1.59M sold.

Pura Vida Investments first reported a position in SAGE in Q2 2015 and held it in 3 quarters. The position peaked at $1.91M in Q2 2015. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

  • Pura Vida Investments reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Pura Vida Investments sold 10,000 Sage Therapeutics shares in Q2 2019, an estimated $1.59M.
  • Pura Vida Investments first reported a position in Sage Therapeutics in Q2 2015 and held it in 3 quarters.
  • Pura Vida Investments's Sage Therapeutics position peaked at $1.91M in Q2 2015.
  • 272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Pura Vida Investments's 13F filing for Q2 2019, filed 14 Aug 2019.